BioPharma M&A Drives More Efficient Resource Allocation

M&A is an omnipresent reality in the biopharma industry, from Big Pharma mega-mergers to smaller acquisitions of emerging startups.

We’ve recently witnessed several large M&A transactions get closed or announced, including BMS-Celgene, Takeda-Shire, and AbbVie-Allergan; according to BMO Capital Markets data, there was nearly $260B in M&A deal activity in 2019. Over the past eight years, we’ve seen over $1 trillion in M&A deal values in aggregate.